Navigation Links
Viron to Present Data from Phase II Trial at American Heart Association Conference
Date:11/11/2009

LONDON, ON, Nov. 11 /PRNewswire/ - Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

The presentation entitled, "Viral Anti-inflammatory Treatment of Unstable Coronary Syndromes: The VT-111 Acute Coronary Syndrome Trial," will disclose recent results from a Phase IIa trial evaluating VT-111, a serine protein inhibitor, in patients with Acute Coronary Syndromes receiving coronary stents. Dr. Tardif's presentation is scheduled for Wednesday, November 18, 2009, at 11:00 AM (ET) in Room W304gh of the Orange County Convention Center. A copy of the presentation will be available after the conference on Viron's website, www.vironinc.com.

About VT-111

VT-111, an immune-modulating protein therapeutic, is the world's first viral-derived human therapeutic. It is a novel inhibitor of the monocyte/macrophage influx to sites of injury and has demonstrated potent efficacy in preclinical models of acute injury in which inflammation plays a key role. VT-111 recently completed a Phase IIa trial of 48 patients with Acute Coronary Syndromes receiving coronary stents. In addition to advancing the cardiovascular program with a partner, Viron is moving to conduct appropriate preclinical studies prior to a clinical program to evaluate the effects of VT-111 in solid organ transplantation.

About Viron Therapeutics Inc. (www.vironinc.com)

Viron is a biopharmaceutical company pioneering the development of pathogen proteins, a revolutionary new class of drugs. These drugs leverage strategies evolved by pathogens to inactivate key targets in the human immune system. The Company's proprietary PROSPECT(TM) technology, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a platform for the discovery of new immune-modulating protein therapeutics. Its significant pipeline of products target critical pathways that have broad application to immune and inflammatory based diseases such as cardiovascular disease and rheumatoid arthritis. VT-111, the Company's lead compound, is in development to treat Acute Coronary Syndromes and solid organ transplant rejection.

SOURCE Viron Therapeutics Inc.


'/>"/>
SOURCE Viron Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. University of Massachusetts Amherst and ADVENTUS Recognize Future Environmental Science Leaders
2. RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products
3. The future of electricity may be found in environmentally friendly, thermoelectric cells
4. The future of electricity may be found in environmentally-friendly, thermoelectric cells
5. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
6. Environmental & Economic Factors Drives Global Demand for Pharmaceutical leak Testing and Deblistering
7. Implementing QA Automation Tools in an FDA Controlled Software Environment, a Free Webinar
8. Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation
9. Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber
10. Hidden diversity in key environmental cleanup microbes found by systems biology assessment
11. How mercury becomes toxic in the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  BioPharmX Corporation (NYSE MKT: ... the dermatology market, today reported financial results for ... and will provide an update on the company,s ... "We are pleased to report that ... BioPharmX," said President Anja Krammer. "We achieved key ...
(Date:3/23/2017)... According to a report by Transparency Market ... due to the presence of a large pool of participants; however, ... , and Sigma-Aldrich, compete with each other in this market. With ... than 76% of this market in 2016.  ... As of now, a large number of ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
(Date:3/22/2017)... 22, 2017 Good Start Genetics, a leading ... the 130 million covered lives mark through its most ... Texas . With newly signed contracts nationally ... enjoy strong payor acceptance based on the quality of ... genetic counseling, its industry-leading customer care and support and ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
Breaking Biology News(10 mins):